Literature DB >> 17874631

[Cyclophosphamide in the therapy of rheumatoid arthritis and its complications].

Jakub Trefler1, Ewa Matyska-Piekarska, Jan K Łacki.   

Abstract

Cyclophosphamide has been used in the therapy of rheumatoid arthritis (RA) for nearly fifty years. An experience gathered throughout that time helped to identify indications, profits, restrictions and side effects related to its use. As a result of the progress in RA therapy in the recent years, including introduction of anti - TNF alpha therapy, the importance of cyclophosphamide significantly decreased. However, despite all restrictions related to its use, there are still RA patients for whom cyclophosphamide can be considered as a first choice drug. In this article we review the current knowledge on the issue.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17874631

Source DB:  PubMed          Journal:  Pol Merkur Lekarski        ISSN: 1426-9686


  2 in total

1.  Protective effect of aminoguanidine against cyclophosphamide-induced oxidative stress and renal damage in rats.

Authors:  Premila Abraham; Suganthy Rabi
Journal:  Redox Rep       Date:  2011       Impact factor: 4.412

2.  Nitrosative stress, protein tyrosine nitration, PARP activation and NAD depletion in the kidneys of rats after single dose of cyclophosphamide.

Authors:  Premila Abraham; Suganthy Rabi
Journal:  Clin Exp Nephrol       Date:  2009-03-07       Impact factor: 2.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.